Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.

NCT07294950 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT07294950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07294950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Phase 3
Overall status
Recruiting
Start date
February 1, 2026
Completion date
May 31, 2029
Enrollment
98 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

appetite regulation, blood pressure monitoring, obesity (disorder), weight change